Bilateral orchiectomy with or without flutamide for metastatic prostate cancer - PubMed (original) (raw)
Clinical Trial
. 1998 Oct 8;339(15):1036-42.
doi: 10.1056/NEJM199810083391504.
B A Blumenstein, E D Crawford, G Miller, D G McLeod, P J Loehrer, G Wilding, K Sears, D J Culkin, I M Thompson Jr, A J Bueschen, B A Lowe
Affiliations
- PMID: 9761805
- DOI: 10.1056/NEJM199810083391504
Free article
Clinical Trial
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
M A Eisenberger et al. N Engl J Med. 1998.
Free article
Abstract
Background: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy.
Methods: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status.
Results: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease.
Conclusions: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Comment in
- Hormonal treatment of prostate cancer.
Garnick MB. Garnick MB. N Engl J Med. 1999 Mar 11;340(10):812-3. doi: 10.1056/NEJM199903113401015. N Engl J Med. 1999. PMID: 10075531 No abstract available. - Disclosure statements regarding hormonal treatment of prostate cancer.
[No authors listed] [No authors listed] N Engl J Med. 1999 May 27;340(21):1689-90. N Engl J Med. 1999. PMID: 10348691 No abstract available.
Similar articles
- Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. James ND, et al. Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19042080 Clinical Trial. - Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G. Labrie F, et al. Prog Clin Biol Res. 1988;260:41-62. Prog Clin Biol Res. 1988. PMID: 3283766 Clinical Trial. - Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Boccon-Gibod L, et al. Eur Urol. 1997;32(4):391-5; discussion 395-6. Eur Urol. 1997. PMID: 9412794 Clinical Trial. - Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G, Kolvenbag G, Nash A. Blackledge G, et al. Anticancer Drugs. 1996 Jan;7(1):27-34. Anticancer Drugs. 1996. PMID: 8742095 Review. - Monotherapy in advanced prostate cancer: an overview.
Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N. Baltogiannis D, et al. Exp Oncol. 2004 Sep;26(3):185-91. Exp Oncol. 2004. PMID: 15494685 Review.
Cited by
- N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.
Chen Y, Lan T. Chen Y, et al. Front Pharmacol. 2024 Sep 18;15:1451957. doi: 10.3389/fphar.2024.1451957. eCollection 2024. Front Pharmacol. 2024. PMID: 39359255 Free PMC article. Review. - Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review.
Meagher MF, Salmasi A, Stewart TF. Meagher MF, et al. Res Rep Urol. 2023 Nov 13;15:509-517. doi: 10.2147/RRU.S398129. eCollection 2023. Res Rep Urol. 2023. PMID: 38025805 Free PMC article. Review. - Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials.
Lee YS, Kim SH, Tae JH, Chang IH, Kim TH, Myung SC, Kim M, Nguyen TT, Choi J, Kim JH, Kim JW, Choi SY. Lee YS, et al. Prostate Int. 2023 Sep;11(3):159-166. doi: 10.1016/j.prnil.2023.06.003. Epub 2023 Jul 4. Prostate Int. 2023. PMID: 37745904 Free PMC article. - A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy.
Yuan F, Wang Y, Xiao X, Zhang X, Jing M, Kamecki H, Tan YG, Barreras SG, Aragon-Ching JB, Ma Z, Zhang P, Chang D, You Y. Yuan F, et al. Transl Androl Urol. 2023 Aug 31;12(8):1336-1350. doi: 10.21037/tau-23-272. Epub 2023 Aug 4. Transl Androl Urol. 2023. PMID: 37680229 Free PMC article. Review. - Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models.
Jeong SH, Kim HH, Park MY, Bhosale PB, Abusaliya A, Won CK, Park KI, Kim E, Heo JD, Kim HW, Ahn M, Seong JK, Kim GS. Jeong SH, et al. Int J Mol Sci. 2023 May 25;24(11):9240. doi: 10.3390/ijms24119240. Int J Mol Sci. 2023. PMID: 37298192 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical